A1AT construct

A1AT construct is a preclinical-stage peptide-protein therapeutic being developed by Paint Therapeutics for the treatment of pulmonary emphysema. The drug is designed as a human surfactant peptide-based elastase inhibitor, specifically engineered for pulmonary delivery. Its mechanism of action involves the inhibition of elastase, an enzyme responsible for the degradation of elastin in lung tissue, which is a primary pathological feature of emphysema. By incorporating a surfactant peptide, the construct is intended to enhance delivery and retention within the lungs, potentially providing a more effective localized treatment compared to systemic alpha-1 antitrypsin replacement therapies.

Other names

human surfactant peptide-elastase inhibitor